Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Short Interest Down 48.5% in September

Unicycive Therapeutics, Inc. (NASDAQ:UNCYGet Free Report) was the target of a large decline in short interest in the month of September. As of September 15th, there was short interest totalling 384,900 shares, a decline of 48.5% from the August 31st total of 746,800 shares. Based on an average daily volume of 2,570,000 shares, the short-interest ratio is currently 0.1 days. Currently, 0.5% of the shares of the company are short sold.

Unicycive Therapeutics Price Performance

Shares of UNCY stock opened at $0.42 on Friday. The company has a market capitalization of $39.33 million, a P/E ratio of -0.35 and a beta of 2.34. The company’s 50-day simple moving average is $0.38 and its two-hundred day simple moving average is $0.76. Unicycive Therapeutics has a one year low of $0.20 and a one year high of $1.82.

Unicycive Therapeutics (NASDAQ:UNCYGet Free Report) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.08. On average, research analysts expect that Unicycive Therapeutics will post -0.26 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on UNCY shares. Benchmark restated a “speculative buy” rating and issued a $3.00 price target on shares of Unicycive Therapeutics in a research note on Friday, September 6th. Brookline Capital Management upgraded shares of Unicycive Therapeutics to a “strong-buy” rating in a research note on Tuesday, July 9th. Finally, HC Wainwright reissued a “buy” rating and set a $2.50 price objective on shares of Unicycive Therapeutics in a research note on Tuesday, September 3rd. Four investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Unicycive Therapeutics has a consensus rating of “Buy” and an average target price of $5.13.

Check Out Our Latest Stock Analysis on Unicycive Therapeutics

Institutional Trading of Unicycive Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Virtu Financial LLC acquired a new position in shares of Unicycive Therapeutics during the first quarter valued at about $36,000. Rosalind Advisors Inc. acquired a new stake in shares of Unicycive Therapeutics in the first quarter worth $2,594,000. Finally, BVF Inc. IL lifted its holdings in shares of Unicycive Therapeutics by 70.5% in the 1st quarter. BVF Inc. IL now owns 3,611,601 shares of the company’s stock valued at $4,984,000 after buying an additional 1,493,462 shares during the period. Hedge funds and other institutional investors own 40.42% of the company’s stock.

Unicycive Therapeutics Company Profile

(Get Free Report)

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.

Read More

Receive News & Ratings for Unicycive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unicycive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.